Larsen FO, et al. - In this study, the effect of adding bevacizumab to chemotherapy in second-line treatment was investigated in patients with advanced biliary tract cancer. Researchers observed that as a second-line treatment, the combination of capecitabine, irinotecan, gemcitabine, and bevacizumab was well tolerated but with a modest, if any, benefit.